Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort

Reference

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–8423.
   PubMed Web of Science ®Google Scholar
• Guedj M, Marisa L, de RA, et al. A refined molecular taxonomy of breast cancer. Oncogene. 2012;31:1196–1206.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
   PubMed Web of Science ®Google Scholar
• Prat A, Adamo B, Fan C, et al. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep. 2013;3:3544.
   PubMed Web of Science ®Google Scholar
• Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24:S26–S35.
   PubMed Web of Science ®Google Scholar
• Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci USA. 1999;96:12589–12594.
   PubMed Web of Science ®Google Scholar
• Prat A, Adamo B, Cheang MC, et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18:123–133.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729–735.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96–110.
   PubMed Web of Science ®Google Scholar
• Milioli HH, Tishchenko I, Riveros C, et al. Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. BMC Med Genomics. 2017;10:19.
   PubMed Web of Science ®Google Scholar
• Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010–8018.
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482–1485.
   PubMed Web of Science ®Google Scholar
• Jung J, Kang E, Gwak JM, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Curr Oncol. 2016;23:298–303.
   PubMed Web of Science ®Google Scholar
• Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010;32:25–33.
   PubMedGoogle Scholar
• Moynahan ME, Chiu JW, Koller BH, et al. Brca1 controls homology-directed DNA repair. Mol Cell. 1999;4:511–518.
   PubMed Web of Science ®Google Scholar
• Prakash R, Zhang Y, Feng W, et al. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7:a016600.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12:587–598.
   PubMed Web of Science ®Google Scholar
• Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26:52–64.
   PubMed Web of Science ®Google Scholar
• Weigman VJ, Chao HH, Shabalin AA, et al. Basal-like breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat. 2012;133:865–880.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–425.
   PubMed Web of Science ®Google Scholar
• Jonson L, Ahlborn LB, Steffensen AY, et al. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer. Breast Cancer Res Treat. 2016;155:215–222.
   PubMed Web of Science ®Google Scholar
• Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Meth. 2015;12:115–121.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.
   PubMed Web of Science ®Google Scholar
• Wickham H. ggplot2: Elegant graphics for data analysis. New York (NY): Springer-Verlag; 2009.
   Google Scholar
• Nielsen FC, van Overeem HT, Sorensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016;16:599–612.
   PubMed Web of Science ®Google Scholar
• Larsen MJ, Kruse TA, Tan Q, et al. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One. 2013;8:e64268.
   PubMed Web of Science ®Google Scholar
• Jonsson G, Staaf J, Vallon-Christersson J, et al. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer. Cancer Res. 2012;72:4028–4036.
   PubMed Web of Science ®Google Scholar
• Hiller DJ, Chu QD. Current status of poly(ADP-ribose) polymerase inhibitors as novel therapeutic agents for triple-negative breast cancer. Int J Breast Cancer. 2012;2012:829315.
   PubMedGoogle Scholar